Introduction {#s1}
============

The epigenome of somatic cells is highly stable. This fundamental principle ensures tissue homeostasis, which prevents epigenetic reprogramming of somatic cells to diseased cell states. In spite of this stability, somatic cells can be reprogrammed to an embryonic stem cell (ESC) like state by a number of procedures, including nuclear transfer, cell fusion and overexpression of transcription factors ([@b27]; [@b45]; [@b46]; [@b47]). These procedures are, however, very inefficient, reflecting a resistance toward reprogramming and the high stability of the differentiated state of somatic cells. The epigenetic factors that restrict somatic cell nuclear reprogramming to pluripotency are ill-defined. Resistance to reprogramming is acquired gradually during embryogenesis as pluripotent cells differentiate into somatic cell lineages ([@b22]; [@b26]). Several layers of epigenetic modifications are likely to be involved and these may be acquired progressively as cells become more restricted during development. Transcription factors, DNA methylation, non-coding RNAs and histone modifications are known to play a role in the maintenance of epigenetic states. However, whether histone variants also restrict somatic cell reprogramming to induced pluripotency is not known.

Histone variants macroH2A are characterized by their large size, which is three times that of canonical histone H2A ([@b38]) and are generally associated with heterochromatin ([@b6]). There are two macroH2A genes in the mouse ([@b16]; [@b38]), termed *macroH2A.1* and *macroH2A.2* in the new histone variant nomenclature, and previously referred to as *macroH2A1* and *macroH2A2* ([@b48]). *MacroH2A.1* can be alternatively spliced to give rise to *macroH2A.1.1* or *macroH2A.1.2* ([@b40]; [@b50]), each of these possessing another variant (*macroH2A.1.s3*, *macroH2A.1.s4* for *macroH2A.1.1*, and *macroH2A.1.s1*, *macroH2A.1.s2* for *macroH2A.1.2*) ([@b4]). In mouse and in humans, in addition to alternative *macroH2A.1* splicing, *macroH2A.1.s3* and *macroH2A.1.s1* also each differ from *macroH2A.1.s4* and *macroH2A.1.s2*, respectively, by a single Lysine residue, the function of which, if any, is currently unknown ([@b4]).

MacroH2A histone variants incorporate into chromatin via their histone H2A-like region, which is attached via a linker region to a bulky non-histone (macro) domain that projects out of the nucleosome ([@b8]). All the three regions of macroH2A are independently associated with transcriptional repression ([@b6]).

MacroH2As are developmentally regulated ([@b12]; [@b10]; [@b39]). *In vivo*, maternal macroH2A.1 is removed from pronuclei prior to the onset of somatic macroH2A expression at the eight-cell stage in the preimplantation embryo, and becomes enriched on the inactive X chromosome (Xi) by the morula stage ([@b12]; [@b17]). MacroH2A.1 is also enriched on the Xi in somatic cells, but not on the Xi of epiblast stem cells, derived from the post-implantation embryo ([@b15]; [@b36]). In the mouse embryo, macroH2A expression has not been investigated after E3.5. In general, *macroH2A.1.1* has been found to be expressed in cells derived from differentiated tissues with low proliferation, whereas *macroH2A.1.2* tends to be more widely expressed including in proliferative cells ([@b39]; [@b40]).

Mice lacking macroH2A.1 or macroH2A.2 are fertile and viable, and display only mild phenotype, including metabolic defects, suggesting that macroH2A is not strictly required for embryonic development in the mouse ([@b5]; [@b6]; [@b13]). Removal of both macroH2A.1 and macroH2A.2 from female mouse ESCs was found to impair ESCs differentiation in one study ([@b18]; [@b19]), while it was not found to prevent X chromosome inactivation and differentiation by another group ([@b49]). Using the heterologous system of mammalian nuclear transfer to *Xenopus* oocytes it was previously shown that the histone variant macroH2A is a component of the epigenetic mechanisms of gene silencing present in somatic cells. However, whether this bears significance for somatic cell epigenome resistance to reprogramming towards pluripotency has not been addressed ([@b37]).

Here, we report that during mouse embryogenesis, macroH2A.1 becomes highly expressed and incorporated into chromatin in somatic cell lineages. Importantly, macroH2A.1 is a structural component of the repressed chromatin of pluripotency genes in somatic cells and acts as an epigenetic barrier to the induction of naïve pluripotency. Our study demonstrates the importance of macroH2A histone variants in maintenance of cellular identity.

Results {#s2}
=======

MacroH2A is a hallmark of somatic cell differentiation *in vivo* {#s2a}
----------------------------------------------------------------

To investigate the expression pattern of macroH2A *in vivo* we carried out wholemount immunofluorescence of E3.5 and E4.5 mouse blastocysts against macroH2A.1 and pluripotency transcription factors Oct4 and Nanog to delineate the ICM. In early blastocysts (E3.5), prior to the establishment of naïve pluripotency, nuclear macroH2A.1 was detected throughout the embryo irrespective of cell lineage ([Fig. 1A](#f01){ref-type="fig"}), which was consistent with a previous report ([@b17]). In contrast, in E4.5 blastocysts, we detected a dramatic decrease of nuclear macroH2A.1 in the ICM in comparison to the trophectoderm with only heterochromatic foci remaining enriched for this histone variant ([Fig. 1B](#f01){ref-type="fig"}). This suggests that the establishment of naïve pluripotency *in vivo* is marked by a downregulation of macroH2A.1 expression.

![**MacroH2A.1 is downregulated in the naïve pluripotent epiblast.** (**A**) E3.5 female mouse blastocyst wholemount immunofluorescence against macroH2A.1 (red in merge panel), Oct4 (blue in merge panel) and Nanog (green in merge panel). Nuclear macroH2A.1 is detected at equivalent levels in cells of the trophectoderm and those of the ICM (dashed lines). Note that naïve pluripotency has not been established in the ICM at this stage. Images are projected confocal Z-sections. (**B**) E4.5 female mouse blastocyst wholemount immunofluorescence against macroH2A.1 (red in merge panel), Oct4 (blue in merge panel) and Nanog (green in merge panel). Nuclear macroH2A.1 is detected at higher levels in cells of the trophectoderm, and is downregulated in cells of the ICM (dashed line), and this is at a stage when naïve pluripotency has been established. Images are projected confocal Z-sections.](jcs-125-24-6094-f01){#f01}

Next, we carried out wholemount immunofluorescence of E6.5 *X-GFP* female mouse conceptus against macroH2A.1 and GFP. The paternally derived *X-GFP* transgene was used as a marker to specifically delineate cells of the epiblast, whose mosaic expression reflects random X chromosome inactivation in female embryos ([@b29]). Remarkably, macroH2A.1 expression was undetectable in the pluripotent epiblast, but it was detected strongly in the nuclei of visceral endoderm cells and to a lesser extent in the nuclei of trophectoderm cells ([Fig. 2A](#f02){ref-type="fig"}; supplementary material Fig. S1A). This mirrors the expression level of macroH2A in cultured cell lines derived from these embryonic lineages, namely epiblast stem cells (EpiSCs) and trophoblast stem (TS) cells ([@b36]).

![**MacroH2A.1 becomes highly expressed during somatic lineage development.** (**A**) E6.5 female *X-GFP* mouse conceptus wholemount immunofluorescence against macroH2A.1 (red in merge panel) and GFP (green in merge panel). MacroH2A.1 is highly expressed in the visceral endoderm (VE) and to some extent in the extra embryonic ectoderm (TE) but is not detected in the epiblast (EPI), precursor of all somatic lineages (mosaic *X-GFP* expression due to random X chromosome inactivation). DAPI is in blue. Images are projected confocal Z-sections. (**B**) Western blot analysis of macroH2A.1 in ESCs, EpiSCs, NSCs and MEFs. All cells are female. Tubulin was used as a loading control. (**C**) Quantification of western blot analysis shown in B. MacroH2A.1 signal was normalized to tubulin and ESCs levels set to 1. MacroH2A.1 expression is lowest in ESCs and increases with the differentiated state in EpiSCs, MEFs and adult NSCs. (**D**) E9.5 female *X-GFP* mouse embryo wholemount immunofluorescence against macroH2A.1 (red) and GFP (green). MacroH2A.1 is expressed throughout all tissues of the embryo at this stage. DAPI is in blue. Images acquired using epifluorescence microscopy. (**E**) E9.5 *X-GFP* mouse embryo immunofluorescence against macroH2A.1 (red) and GFP (green) showing a portion of the lateral plate mesoderm (including somites). Nuclear macroH2A.1 is detected in all somatic cells. Mosaic *X-GFP* expression is due to random X chromosome inactivation. DAPI is in blue. Images are projected confocal Z-sections. Scale bars: 20 µm.](jcs-125-24-6094-f02){#f02}

Subsequently, we compared macroH2A.1 expression in *in vitro* cultures of pluripotent and somatic cells. We found that macroH2A.1 was quantitatively more abundant in mouse embryonic fibroblasts (MEFs) and adult neural stem cells (NSCs) compared to undifferentiated ESCs and EpiSCs ([Fig. 2B,C](#f02){ref-type="fig"}). To assess whether macroH2A.1 expression is correlated with the differentiated state of cells in developing mouse embryos, we probed its expression later in development, in E9.5 embryos, in which somatic cell lineage determination has occurred. Nuclear macroH2A.1 was strongly detected throughout all somatic cells of E9.5 embryos, irrespective of their sex and X chromosome inactivation status ([Fig. 2D,E](#f02){ref-type="fig"}; supplementary material Fig. S1B). The accumulation of nuclear macroH2A.1 in differentiated cells was in striking contrast to its low levels in mouse pluripotent ICM, post-implantation epiblast, germline ([@b30]) and zygote ([@b12]; [@b34]). We conclude that macroH2A.1 marks the post-gastrulation embryo concomitantly with somatic cell lineage commitment and thereby can be considered a hallmark of somatic cell differentiation *in vivo*.

MacroH2A.1 is a chromatin component of repressed pluripotency genes in differentiated cells {#s2b}
-------------------------------------------------------------------------------------------

Genome-wide analysis of macroH2A variants established that they generally localize to heterochromatic regions ([@b3]; [@b7]; [@b14]; [@b18]; [@b24]). At the same time, they can also be found in the coding regions of a small proportion of genes whose expression level inversely correlates with the amount of macroH2A incorporated in their chromatin ([@b23]; [@b24]). Since the presence of macroH2A is mostly considered to have a repressive effect on genes and its abundance correlates with cell differentiation, we hypothesized that it may be incorporated in the chromatin of repressed pluripotency genes in somatic cells. We carried out ChIP analysis in undifferentiated ESCs, MEFs and adult NSCs. In ESCs, macroH2A.1 was detected at low levels in the regulatory sequences of pluripotency genes, *Oct4* and *Sox2*, lineage-specific genes, *B-Globin* and *Thy1*, and the housekeeping genes *GAPDH* and *c-Jun* ([Fig. 3](#f03){ref-type="fig"}). In somatic cells, both in mouse embryonic fibroblasts (MEFs) and in NSCs, macroH2A.1 became markedly enriched in the regulatory sequences of *Oct4*, *B-Globin* and *Thy1*, correlating with the repressed state of these genes in these cells. MacroH2A.1 did not become enriched in the *GAPDH* and *c-Jun* promoter, active in all cell types analyzed ([Fig. 3](#f03){ref-type="fig"}). MacroH2A.1 was highly enriched in the chromatin of *Sox2* regulatory regions in MEFs but not in NSCs in which this gene is highly expressed. In conclusion, the histone variant macroH2A.1 incorporates into the nucleosomes in the regulatory sequences of both repressed pluripotency and lineage-specific genes in somatic cells linking macroH2A not only to gene silencing but also to the stabilization of the differentiated cell state.

![**MacroH2A.1 marks chromatin of regulatory sequences of repressed pluripotency genes in differentiated cells.** MacroH2A.1 ChIP analysis of pluripotent and lineage-specific gene regulatory regions in pluripotent (ESCs, light gray), and somatic cells (NSCs, gray; MEFs, dark gray). DE, distal enhancer; PE, proximal enhancer; PP, proximal promoter; RR1, regulatory region 1; RR2, regulatory region 2. Error bars depict the s.e.m. (*n* = 3). There were significant differences between ESCs and NSCs or MEFs, as indicated; \**P*\<0.05; *t*-test one tail, type 3.](jcs-125-24-6094-f03){#f03}

MacroH2A acts as an epigenetic barrier to induced pluripotency {#s2c}
--------------------------------------------------------------

The correlation of macroH2A abundance with increased cell differentiation *in vivo* and its incorporation into the chromatin of repressed genes in somatic cells may indicate that histone variants macroH2A help stabilize the differentiated cell state. If this is the case, then macroH2A should represent an epigenetic barrier to somatic cell reprogramming toward pluripotency. To test that, we established adult female *Oct4-GFP* NSC lines stably expressing shRNAs targeting macroH2A.1 (macroH2A.1.1 and macroH2A.1.2), macroH2A.2, macroH2A.1 and macroH2A.2, or scrambled shRNA. qRT-PCR confirmed efficient macroH2A depletion in the established cell lines ([Fig. 4A](#f04){ref-type="fig"}). NSCs can be reprogrammed to naïve pluripotency and form induced pluripotent stem cells (iPSCs) through retroviral expression of Oct4 and Klf4 transcription factors ([@b33]; [@b41]). The infected cells give rise to reprogramming intermediates, pre-iPSCs, in serum/leukemia inhibitory factor (LIF) culture conditions, and can be induced to undergo complete reprogramming, characterized by *Oct4-GFP* reporter transgene reactivation, upon the switch to culture conditions consisting of a combination of MEK/ERK-signaling inhibitor and GSK3β inhibitor (2i) with LIF ([@b41]). We infected stable macroH2A- or scramble-shRNA expressing NSC lines with retroviruses encoding Oct4 and Klf4 and cultured the cells in serum/LIF culture conditions ([Fig. 4B](#f04){ref-type="fig"}). Remarkably, without switching to 2i/LIF culture conditions, we started to observe the emergence of Oct4-GFP positive colonies in macroH2A-depleted, but not in control infections 19-20 days post-infection ([Fig. 4C](#f04){ref-type="fig"}). We performed flow cytometry analysis 24 days post-infection to assess the efficiency of reprogramming, as judged by *Oct4-GFP* reactivation ([Fig. 4D](#f04){ref-type="fig"}). Infections of the macroH2A.1, macroH2A.2 and macroH2A.1 plus macroH2A.2 depleted cells contained 1.26%, 3.34% and 2.38% GFP-positive cells, respectively, indicating a 10- to 25-fold increase over control macroH2A containing cells (0.12% GFP positive cells) ([Fig. 4E](#f04){ref-type="fig"}). We did not observe GFP positive colonies in the control infections within the experimental timeframe ([Fig. 4C](#f04){ref-type="fig"}). We conclude that the removal of macroH2A.1 from somatic cells increases the efficiency of iPSCs generation.

![**MacroH2A acts as a barrier to somatic cell reprogramming to pluripotency.** (**A**) qRT-PCR analysis of macroH2A.1 (blue) and macroH2A.2 (purple) expression in Oct4-GFP NSCs stably expressing Scr shRNA, macroH2A.1 shRNA, macroH2A.2 shRNA or both macroH2A.1 and macroH2A.2 shRNAs. Error bars indicate s.d. (**B**) Diagram showing the experimental set up. Stable Oct4-GFP NSCs lines expressing shRNAs against macroH2A.1, macroH2A.2 or both macroH2A.1 and macroH2A.2, or control scrambled sequence (Scr), were generated and induced to reprogram following retroviral-mediated Oct4 and Klf4 expression under serum and LIF culture conditions from 3 days after factor expression. (**C**) MacroH2A depletion improves the efficiency of reprogramming to pluripotency. Oct4-GFP-positive colonies obtained from expression of Oct4 and Klf4 in macroH2A shRNA *Oct4-GFP* NSCs cultured with serum and LIF in the absence of 2i. Note that no Oct4-GFP colonies were obtained from shRNA-expressing cells induced to reprogram within the experimental time frame. Images were taken 24 days following retroviral pluripotency gene expression. (**D**) Flow cytometry analysis of reprogramming cultures. The proportion of Oct4-GFP-positive cells 24 days after the induction of nuclear reprogramming is indicated (% total cells). Oct4-GFP NSCs and Oct4-GFP ESCs were used as controls. Results are representative of two experiments. (**E**) Reprogramming efficiency as judged by the proportion of Oct4-GFP-positive cells.](jcs-125-24-6094-f04){#f04}

To characterize the obtained iPSCs, several colonies were picked and expanded. The established iPSC lines had characteristic ESC morphology and maintained Oct4-GFP expression ([Fig. 5A](#f05){ref-type="fig"}). Since shRNAs against macroH2A were expressed from polymerase-III H1-RNA promoter, their expression was not silenced upon the establishment of pluripotency. Surprisingly, the obtained iPSCs exhibited almost complete loss of expression of the histone variant being knocked down ([Fig. 5B,C](#f05){ref-type="fig"}), which potentially indicates strong selection for cells with the lowest macroH2A levels during the reprogramming process. qRT-PCR analysis of these shRNA iPSCs demonstrated complete silencing of the retroviral transgenes used to overexpress Oct4 and Klf4 in NSCs ([Fig. 6A](#f06){ref-type="fig"}) and the upregulation of endogenous pluripotency markers *Oct4*, *Nanog*, *Rex1* and *Klf4* to levels comparable to ESCs ([Fig. 6B](#f06){ref-type="fig"}). The obtained iPSCs also reactivated the silent X-chromosome as indicated by the loss of the trimethyl(me3)H3K27 nuclear focus (supplementary material Fig. S2). When injected into a kidney capsule, macroH2A shRNA iPSCs generated teratomas with tissues of three embryonic lineages present ([Fig. 6C](#f06){ref-type="fig"}). Moreover, when injected into blastocysts, macroH2A shRNA iPSCs contributed to the embryo and generated coat color chimeras, demonstrating their wide developmental potential ([Fig. 6D](#f06){ref-type="fig"}). Interestingly, some of the double macroH2A.1 and macroH2A.2 shRNA chimeras, but not macroH2A.1 or macroH2A.2 shRNA only, exhibited a range of developmental and morphological defects at different times after birth (supplementary material Fig. S3), which may be a result of improper maintenance of gene silencing in the absence of all macroH2A variants.

![**MacroH2A knockdown is maintained in the obtained iPSCs.** (**A**) Morphology of the iPSCs obtained from reprogrammed macroH2A-depleted NSCs. (**B**) qRT-PCR analysis of *macroH2A.1* and *macroH2A.2* expression in NSCs, ESCs and iPSCs derived from macroH2A.1- or macroH2A.2-depleted NSCs. MacroH2A.1 (*macroH2A.1.1* + *macroH2A.1.2*) is in blue, macroH2A.2 is in purple. Error bars indicate s.d. (**C**) Western blot analysis of macroH2A.1 in shRNA NSCs and macroH2A shRNA iPSCs. Histone H3 was used as a loading control.](jcs-125-24-6094-f05){#f05}

![**Characterization of macroH2A-depleted iPSCs.** (**A**) qRT-PCR analysis of retrovirus expression in NSCs, NS Pre-iPSCs and in iPSCs derived from macroH2A.1 or macroH2A.2 NSCs. Klf4 retrovirus (RetrKlf4) is in blue and Oct4 retrovirus (RetrOct4) in red. (**B**) Gene expression analysis of the iPSCs depleted of macroH2A. qRT-PCR analysis of pluripotency gene expression in NSCs, ESCs and iPSCs derived from macroH2A.1 or macroH2A.2 NSCs. Endogenous Oct4 (EndOct4) is in blue, Rex1 in red, Klf4 in purple and Nanog in green. (**C**) Tissues of the three embryonic germ layers are present in the teratomas derived from macroH2A.2 shRNA expressing iPSCs. (**D**) Contribution of macroH2A-depleted iPSCs to chimeric mice. These were obtained after blastocyst injection of macroH2A shRNA iPSCs into C57/BL6 blastocysts. Agouti coat color indicates chimerism (arrows). Error bars indicate s.d.](jcs-125-24-6094-f06){#f06}

We hypothesized that if indeed macroH2A serves as a barrier to induced pluripotency, then its overexpression in EpiSCs, which naturally express lower levels of this histone variant compared to somatic cells ([Fig. 2B,C](#f02){ref-type="fig"}), would decrease the efficiency of their conversion to naïve pluripotency. EpiSCs can be reprogrammed to naïve pluripotency by overexpression of a single factor such as Nanog or Klf4 together with a switch to 2i plus LIF culture conditions ([@b25]; [@b42]; [@b51]). We transfected EpiSCs carrying the Oct4-GFP reporter (distal enhancer) with transgenes encoding Nanog in combination with macroH2A isoforms or an empty vector control and kept them under dual selection for 2 weeks ([Fig. 7A](#f07){ref-type="fig"}). *MacroH2A* isoforms *macroH2A.1.s1*, *macroH2A.1.s2*, *macroH2A.1.s4* or *macroH2A.2* were used, and overexpression confirmed by qRT-PCR ([Fig. 7D](#f07){ref-type="fig"}). The expression of Oct4 was not changed in the selected EpiSCs, and these maintained normal EpiSCs morphology ([Fig. 7E](#f07){ref-type="fig"}). To induce reprogramming to naïve pluripotency, Oct4-GFP EpiSCs expressing combinations of transgenes were replated at equal densities and subsequently switched to 2i plus LIF conditions for 9 days ([Fig. 7A](#f07){ref-type="fig"}). The appearance of EpiSCs derived iPSCs (Epi-iPSCs) colonies, characterized by response to 2i plus LIF culture conditions and Oct4-GFP reporter expression, was monitored. Remarkably, macroH2A overexpression in EpiSCs dramatically reduced the number of emerging 2i plus LIF Oct4-GFP positive Epi-iPSC colonies, indicating that macroH2A negatively regulates the efficiency of EpiSCs reprogramming to naïve pluripotency ([Fig. 7B,C](#f07){ref-type="fig"}). Overexpression of individual macroH2A.1 isoforms reduced reprogramming efficiency by 9- to 15-fold and in the case of macroH2A.2 no colonies were obtained. To assay the expression of macroH2A and pluripotency genes in the obtained Epi-iPSCs, several of these were picked, expanded, and subjected to qRT-PCR analysis ([Fig. 7D,E](#f07){ref-type="fig"}). The Epi-iPSCs obtained showed pluripotency gene expression levels comparable to control ESCs ([Fig. 7E](#f07){ref-type="fig"}). We conclude that overexpression of macroH2A impairs the reprogramming of EpiSCs to naïve pluripotency.

![**MacroH2A overexpression prevents efficient reprogramming of EpiSC to naïve pluripotency.** (**A**) Diagram showing the experimental set up. Oct4-GFP EpiSCs were transfected with vectors encoding *Nanog* in combination with *macroH2A.1.s1*, *macroH2A.1.s2*, *macroH2A.1.s4*, *macroH2A.2* or empty vector control and grown for 2 weeks under dual selection. Selected cells were plated at a density of 50,000 cells per well of a six-well plate, switched to 2i plus LIF the next day and cultured for another 9 days before monitoring the presence of reprogrammed Oct4-GFP-positive Epi-iPSCs. (**B**) Representative phase and GFP images taken 9 days after the 2i plus LIF culture of Oct4-GFP EpiSC with Nanog and macroH2A variants or empty vector overexpression. (**C**) Oct4-GFP-positive Epi-iPSCs colony counts. The average number of Oct4-GFP-positive Epi-iPSCs per well 9 days after the switch of macroH2A overexpressing or control cells to 2i plus LIF conditions is indicated. Values represent the average colony number from three independent wells. (**D**) qRT-PCR analysis of *macroH2A.1* (light blue) and *macroH2A.2* (purple) in Oct4-GFP EpiSCs transfected with *Nanog* (+Nanog) and *macroH2A.1.s1* (+.1.s1), *macroH2A.1.s2* (+.1.s2), *macroH2A.1.s4* (+.1.s4), *macroH2A.2* (+.2) or empty vector control (+empty); and in the resulting Oct4-GFP Epi-iPSCs, as well as control Oct4-GFP ESCs. (**E**) qRT-PCR analysis of *Esrrb* (light blue), *Rex1* (red), *Oct4* (green) and *Klf4* (purple) in Oct4-GFP EpiSCs transfected with *Nanog* (+Nanog) and *macroH2A.1.s1* (+.1.s1), *macroH2A.1.s2* (+.1.s2), *macroH2A.1.s4* (+.1.s4), *macroH2A.2* (+.2) or empty vector control (+empty); and in the resulting Oct4-GFP Epi-iPSCs and control Oct4-GFP ESCs. Please note control Oct4-GFP ESCs express Nanog, but do not overexpress Nanog. Error bars indicate s.d.](jcs-125-24-6094-f07){#f07}

Given that macroH2A incorporates in silenced pluripotency genes in somatic cells and that it prevents efficient reprogramming to induced pluripotency, we sought to determine whether macroH2A overexpression in ESCs induces differentiation and/or pluripotency gene repression. Overexpression of *macroH2A.1.s1*, *macroH2A.1.s2*, *macroH2A.1.s4* and *macroH2A.2* in ESCs did not induce cell death or differentiation and the obtained ESCs maintained ESC morphology, indicating that ectopic macroH2A expression is compatible with maintenance of pluripotency ([Fig. 8A](#f08){ref-type="fig"}). ESCs overexpressing macroH2A isoforms showed a modest decrease in pluripotency gene expression and an increase in basal expression levels of the differentiation mesoderm marker *T-Brachyury*, but little changes in the expression of *Gata4* ([Fig. 8B,C](#f08){ref-type="fig"}). We conclude that ectopic macroH2A expression in ESCs, though leading to some downregulation of pluripotency markers and misexpression of a mesoderm marker, is not an inducer of ESCs differentiation.

![**MacroH2A overexpression in ESCs.** (**A**) qRT-PCR analysis of *macroH2A.1* and *macroH2A.2* expression in ESCs overexpressing *macroH2A.1.s1*, *macroH2A.1.s2*, *macroH2A.1.s4* and *macroH2A.2*, or empty vector control. *MacroH2A.1* is in blue and *macroH2A.2* in purple. (**B**) qRT-PCR analysis of *Nanog*, *Klf4* and *Esrrb* expression in ESCs overexpressing *macroH2A.1.s1*, *macroH2A.1.s2*, *macroH2A.1.s4* and *macroH2A.2*, or empty vector control. *Nanog* is in blue, *Klf4* in red and *Esrrb* in green. (**C**) qRT-PCR analysis of *T-Brachyury* and *Gata4* expression in ESCs overexpressing *macroH2A.1.s1*, *macroH2A.1.s2*, *macroH2A.1.s4* and *macroH2A.2*, or empty vector control. *T-Brachyury* is in blue and *Gata4* in purple. Error bars indicate s.d.](jcs-125-24-6094-f08){#f08}

The increased efficiency of somatic cell reprogramming upon the removal of macroH2A and the decreased efficiency of EpiSC reprogramming upon macroH2A overexpression, together with the fact that macroH2A is a chromatin component of repressed pluripotency genes in somatic cells indicates that macroH2A histone variants represent an epigenetic barrier to cell reprogramming to naïve pluripotency.

Discussion {#s3}
==========

In this study, we report that the histone variant macroH2A is present at low levels in the pluripotent cell compartment of pre- and post-implantation mouse embryos while it accumulates to high levels in somatic cells *in vivo* as well as *in vitro*. This observed correlation of macroH2A abundance with the degree of cell differentiation together with the known gene repression functions of these histone variants suggests that macroH2A is involved in gene repression during cell commitment. These findings are consistent with previous reports showing high macroH2A expression in differentiated cells both in mouse and human ([@b18]; [@b21]; [@b39]).

In somatic cells, macroH2A depletion, though causing decreased stability of silencing of the inactive X chromosome and pluripotency genes ([@b20]; [@b36]), is not sufficient to induce full reactivation of repressed genes, or a change in cell fate. At the same time, when exposed to reprogramming conditions, as we show in this study, cells depleted of macroH2A are induced to reprogram with higher efficiencies. Moreover, ectopic macroH2A expression strongly impairs EpiSCs reprogramming to naïve pluripotency. These results suggest that late incorporation of macroH2A into chromatin of repressed genes during development is important to stabilize their silenced state and thereby contribute to the maintenance of the differentiated state of somatic cells. Whether macroH2A also restricts direct reprogramming of one somatic cell type to another warrants further investigations.

A key mechanistic step during nuclear reprogramming may be chromatin decompaction, which gives reprogramming factors access to pluripotency gene regulatory regions. MacroH2A variants in a nucleosome have been shown to promote chromatin compaction by multiple mechanisms. We believe that the removal of macroH2A makes chromatin more accessible to respond to transcription factors Oct4 and Klf4, thereby facilitating transcriptional activation of target genes and cell state transitions during somatic cell reprogramming. MacroH2A has been reported to promote chromatin compaction ([@b1]; [@b9]), recruitment of histone deacetylases ([@b8]), lower the affinity for SWI/SNF chromatin remodeling complexes ([@b11]), hinder transcription factor binding ([@b2]) and associate with Polycomb proteins Ezh2 and Suz12 ([@b7]). These repressive functions attributed to macroH2A variants, acting together with other epigenetic mechanisms such as DNA methylation and Polycomb, are likely to be mechanistically linked to the low efficiency of nuclear reprogramming. Indeed, genetic ablation of HDAC2 or its chemical inhibition improves the efficiency with which somatic cells can be induced to pluripotency ([@b31]).

Importantly, not only does macroH2A restrict induced pluripotency and transcriptional reactivation, but it also prevents progression of melanomas to the metastatic state ([@b32]). Indeed, loss of macroH2A.1.1 is seen in several cancer types and correlates with negative outcome for patients with lung or colorectal cancer ([@b32]; [@b35]; [@b43]; [@b44]). This reinforces the view that loss of macroH2A is associated with decreased long-term somatic cell stability. Interestingly, macroH2A.1 shRNA iPSCs were devoid of detectable macroH2A.1, unlike macroH2A.1 shRNA NSCs, indicating a possible selection for cells with low macroH2A.1 expression during reprogramming to induced pluripotency. This seems particularly relevant in light of the increased metastatic and teratogenic state of macroH2A depleted cells ([@b18]; [@b32]). Thus, it would be of interest to explore the process of induced pluripotency as a route to identify novel developmentally regulated epigenetic barriers not only to nuclear reprogramming but also to cancer progression.

Overexpression of macroH2As in ESCs, EpiSCs or Epi-iPSCs did not lead to cell differentiation or detectable morphological changes, but for ESCs it did cause a small reduction in pluripotency gene expression and an increase in the expression of mesoderm inducer *T-Brachyury*. This suggests that high levels of multiple macroH2A isoforms are compatible with pluripotency. This is in agreement with the high expression of pluripotency genes in Epi-iPSCs in which high levels of macroH2A isoforms in combination with Nanog are expressed. At the same time, macroH2A overexpression could prone ESCs for differentiation. Interestingly, *T-Brachyury* expression was found to be impaired in ESCs depleted of macroH2A.1 and induced to differentiate using retinoic acid ([@b18]).

Genetic ablation of macroH2A.1 or macroH2A.2 is not lethal and results in fertile mice, strongly suggesting that individually these histone variants are dispensable for normal embryonic development ([@b13]; [@b14]). Double knockout mice were not reported to date, which leaves open the question whether there are compensatory mechanisms between the two variants. In this study, we observed developmental and morphological abnormalities in chimeric mice obtained from double macroH2A.1 and macroH2A.2 shRNA iPSCs, but not from iPSCs in which individual macroH2A variants were depleted (supplementary material Fig. S3). This may suggest that the knockout phenotype in previous reports could have been masked by potential compensatory mechanisms, which requires further confirmation by combined genetic ablation. Given that macroH2A is required to stabilize the silenced state of repressed genes, the interpretation of the knockout phenotype should include the analysis of susceptibility to cancer, the efficiency of regeneration and germ cell formation and the analysis of the effect of various stress conditions on an organism. It is also possible that macroH2As are not strictly required for embryogenesis, but play a role in maintenance of somatic cell identity, consistent with its known functions in maintenance of silenced states as well as acting as a barrier to reprogramming to pluripotency.

In summary, this study provides evidence that histone variants macroH2A are developmentally regulated epigenetic marks being produced and incorporated into the chromatin of repressed genes concomitantly with cell lineage commitment. Thus, for the first time we identified a link between an epigenetic mark and stabilization of the differentiated cell state that in turn antagonizes induction of pluripotency.

Materials and Methods {#s4}
=====================

Cell culture {#s4a}
------------

Pre-iPS, iPS and PLAT-E cells were cultured in GMEM containing 10% FCS, 1× NEAA, 1× Pen/Strep, 1 mM sodium pyruvate, 0.1 mM 2-mercaptoethanol, 2 mM L-glutamine, supplemented with LIF. NSCs were maintained in homemade NS medium \[DMEM/F-12, 1× NEAA, 0.1 mM 2-mercaptoethanol, 1× Pen/Strep, 1∶100 B27 supplement (Invitrogen), 1∶200 N2 supplement (PAA), 4.5 µM HEPES (PAA), 0.03 M glucose (Sigma-Aldrich), 120 µg/ml BSA (Invitrogen)\] supplemented with 10 ng/ml of EGF and 20 ng/ml of FGF2. EpiSCs were grown and induced to reprogram as described previously ([@b25]; [@b42]).

Plasmids {#s4b}
--------

pMXs-Oct3/4, pMXs-Klf4 (from Addgene). Retroviral infection and plasmids for macroH2A RNAi, as well as primers used to amplify macroH2A isoforms are described elsewhere ([@b36]). For EpiSC reprogramming experiments, plasmids pPB-CAG-macroH2A.1.s1-pA-PGK-hph, pPB-CAG-macroH2A.1.s2-pA-PGK-hph, pPB-CAG-macroH2A.1.s4-pA-PGK-hph, pPB-CAG-macroH2A.2-pA-PGK-hph and pPB-CAG-Nanog-IRES-bsd were used.

Retroviral infection {#s4c}
--------------------

PLAT-E cells were transfected using FuGENE 6 transfection reagent (Roche) according to manufacturer\'s instructions. One day after the transfection complete medium change was performed and 8×10^5^ NSCs were seeded per well of a six-well plate. The following day virus-containing supernatants from PLAT-E cultures were filtered through 0.45 µm cellulose acetate filters and mixed with polybrene (Sigma-Aldrich) to the final concentration of 4 µg/ml. The polybrene/virus mixture was applied to NSCs and these were incubated in virus-containing medium for 24 hours after which the medium was replaced with NS medium. For reprogramming experiments, the infected cells were switched to serum/LIF medium 3 days after infection.

Flow cytometry {#s4d}
--------------

Flow cytometry was performed using BD LSRFortessa cell analyzer with subsequent data analysis using FlowJo software. Cell sorting was performed using a MoFlo high-speed cell sorter.

ChIP analysis {#s4e}
-------------

*Starting material:* 2--10×10^6^ cells, trypsinized off culture plates, washed in complete DMEM, and washed twice in PBS to remove excess serum.

*Fixation:* Cells are suspended in 0.3 ml PBS to which 0.1 ml 4% paraformaldehyde in 1× PBS is added for 7 minutes at room temperature and quenched with 0.4 ml 250 mM cold glycine (125 mM final concentration). Cells are then washed twice in 2× PBS (and stored at −80°C as pellets).

*Lysis:* Cell pellets are resuspended in Lysis buffer (made from 2× stock with protease inhibitor, SDS and DTT added on the day) to a final volume of not more than 270 ml in Protein Lobind 1.5 ml microcentrifuge tubes (Eppendorf). Cells kept on ice with occasional tapping of the tubes for 10 minutes.

*Chromatin fragmentation:* The lysate is sonicated sufficiently to yield chromatin fragments of 250--700 bps using a Bioruptor sonicator (twice for 7-10 minutes with 30 seconds on/off time, on 'high' power, Diagenode). Chromatin is cleared by centrifugation (10 minutes at 10,000 r.p.m. at 4°C). Fragmented chromatin was stored at −80°C.

Chromatin fragment size determination was established by purifying a known amount of the chromatin lysate by the purification procedure described below. Purified DNA was analyzed by gel electrophoresis, post stained with ethidium bromide for fragment sizes. Purified DNA was quantified by UV spectrophotometry (Nanodrop) in order to establish the approximate chromatin concentration of the lysates (approximately twice the DNA concentration). Chromatin lysate were aliquoted into units of ∼25 mg of chromatin (about 27 µl each from 10^7^ cells).

*Pre-adsorption of beads:* An equal volume of Protein A and Protein G magnetic beads (DynaBead, Invitrogen) were mixed together (10 µl each per pull-down tube) and washed three times in RIPA Buffer. Beads were resuspended in SDS free RIPA with BSA (0.1 µg/µl, Sigma) and ssDNA (75 ng/µl, Salmon Sperm derived, Sigma) at a volume of 20 µl/IP and rotated for 30 minutes to 4 hours at 4°C. Beads were then washed once in RIPA (no SDS) and resuspended in RIPA (with BSA and ssDNA and without SDS, such that there were 20 µl/IP.

*Immunocomplex and chromatin pull-down:* A 1∶10 or 1∶20 dilution of chromatin was made in elution buffer and stored at −80°C as 'input sample'. For each pull down series. 25 µg of chromatin was diluted 1∶10 in SDS-free RIPA buffer containing (0.1 µg/µl BSA (Sigma) and 75 ng/µl ssDNA (Salmon Sperm, Sigma-Aldrich). Antibody (20--40 µl total) diluted in SDS-free RIPA (with DNA and BSA) to give 1--10 mg (exact amount as per manufacturer\'s suggestion) were added to this and rotated at 4°C for 20--60 minutes. 20 µl of pre-adsorbed protein A/G beads were then added to each pull down and rotate for 4 hours or overnight at 4°C.

*Capture of immunocomplexes and stringency wash:* Beads were captured on magnetic rack, washed three times in 1 ml low wash buffer, washed in 1 ml high wash buffer. Complexes were eluted from protein A/G by adding 120 ml of elution buffer and incubated at 30°C for 15--20 minutes (avoid foaming). Chromatin was dissociated from beads magnetically and the solution transferred to new DNA LoBind tubes (Eppendorf).

*DNA purification:* RNase A was added (1 µl of DNase free 1 mg/ml to each tube) to 'Input' and chromatin samples pulled down and heated at 65°C for 6 hours or overnight. Samples were tapped up occasionally to move around. DNA was purified with PCR spin columns (Qiagen) and eluted with 2× 60 µl.

*Buffers: ChIP lysis buffer* (50 mM HEPES-KOH pH 7.5, 140 mM NaCl, 5 mM EDTA pH 8, 1% Triton X-100, 0.5% NP-40. 0.5 mM DTT, Protease inhibitor \[Roche, Complete EDTA free\] and 1% SDS added on the day of use). *ChIP RIPA buffer*, *SDS free* \[50 mM Tris-HCl pH 8, 150 mM NaCl, 2 mM EDTA pH 8, 1% NP-40, 0.5% sodium deoxycholate, protease inhibitors (add freshly)\]. *ChIP low wash buffer* (0.1% SDS, 1% Triton X-100, 2 mM EDTA pH 8, 150 mM NaCl, 20 mM Tris-HCl pH 8). *ChIP high wash buffer* (0.1% SDS, 1% Triton X-100, 2 mM EDTA pH 8, 500 mM NaCl, 20 mM Tris-HCl pH 8). *ChIP elution buffer* (1% SDS, 100 mM NaHCO~3~).

*Antibodies used:* macroH2A.1: Upstate 07-219 and Abcam ab37264. H3K9ac: Cell Signaling no. 9649. The primers used are listed in supplementary material Table S1.

Embryo collection and culture {#s4f}
-----------------------------

F1 females from C57B16×CBA crosses were superovulated by intra-peritoneal injection of 10 IU of PMSG (Intervet) and 10 IU of hCG 48 hours later. Matings with F1 males\\males expressing EGFP-H2B ([@b28]) were set up overnight, and the mice were separated the following morning. Mice were sacrificed by cervical dislocation and their oviducts were microdissected in M2 medium to collect the embryonic stage required. Zygotes (embryonic day 0.5; E0.5) were released by oviduct incision, cumulus cells were removed using short hyaluronidase treatment (1 mg/ml). Embryo culture was carried out at 37.5°C in pre-equilibrated KSOM medium under paraffin oil in an incubator with 5% CO~2~.

Wholemount immunofluorescence {#s4g}
-----------------------------

Embryos at E3.5 and E4.5 stages were fixed for 10 minutes in 4% paraformaldehyde in 1× PBS at 37°C. Embryos at E6.5 and E9.5 were fixed for 2 hours in 4% paraformaldehyde in 1× PBS at 37°C. Fixed embryos were rinsed twice in PBS 0.2% Tween (PBT). Permeabilization was carried out during 20 minutes in 0.5% Triton X, followed by the three washes in 1× PBT. The embryos were blocked in 5% fetal bovine serum (FBS) in 1× PBT (blocking) overnight. Primary antibodies overnight incubations were performed at 4°C. Embryos were washed three times for 10--15 minutes in PBT, before detection using secondary antibodies, 2 hours at room temperature followed by three washes in PBT and counterstaining with DAPI. Embryos were imaged using confocal and epifluoresence microscopy. The primary antibodies used were: rabbit IgG anti-mouse macroH2A.1 (1∶100, kind gift from Dr Theodore Rasmussen), rat IgG2 anti-GFP (1∶500, Nacalai Tesque, Cat. No. 04404-26). The secondary antibodies used were: Alexa Fluor 594 anti-rabbit IgG (1∶200, Invitrogen), Alexa Fluor 488 anti-rat (1∶200, Invitrogen), Alexa Fluor 647 anti-mouse (1∶200, Invitrogen).

Immunofluorescence of cultured cells {#s4h}
------------------------------------

Cells grown on glass slides, rinsed in 1× PBS, washed 30 seconds in CSK buffer (100 mM NaCl, 3 mM MgCl~2~, 300 mM sucrose, 10 mM PIPES pH 6.8), 30 seconds in 0.5% Triton X CSK buffer and fixed in 4% PFA 10 minutes before rinsing in 1× PBS 0.2% Tween 20 (PBT). Permeabilized cells were incubated in blocking buffer (5% FBS in 1× PBT) for 30 minutes, then incubated in blocking buffer with primary antibodies overnight at 4°C. The next day, slides were rinsed three times for 10 minutes in PBT and incubated for 30 minutes in blocking buffer with secondary antibodies at room temperature, followed by three washes in PBT and counterstained with DAPI. Slides were mounted with vectashield and imaged using confocal microscopy. The primary antibodies used were: rabbit IgG anti-macroH2A.1 (1∶100, Upstate, Cat. no. 07-219, Lot 32188), mouse IgG3 anti-H3K27me3 (1∶100, AbCam ab6002), mouse IgG2b anti-Oct4 (1∶200 Santa-Cruz C10, SC5279), rat IgG2a anti-Nanog (1∶200, eBioscience, clone eBioMLC-51, 14-5761-80). The secondary antibodies used were: Alexa Fluor 488 anti-mouse IgG (1∶200, Invitrogen), Alexa Fluor 488 goat anti-rat (1∶200, Invitrogen), Alexa Fluor 594 goat anti-rabbit IgG (1∶200, Invitrogen), Alexa Fluor 647 donkey anti-mouse (1∶200, Invitrogen).

Quantitative RT-PCR {#s4i}
-------------------

Total RNA was isolated using RNeasy kit (QIAGEN) in accordance with manufacturer\'s protocol. Reverse transcription was performed using SuperScript III First-Strand Synthesis SuperMix (Invitrogen). qRT-PCR reactions were performed in triplicate using SYBR Green PCR Master Mix or TaqMan Universal PCR Master Mix (both Applied Biosystems). qRT-PCR primers and gene specific Taqman expression assays (Applied Biosystems) are listed in supplementary material Table S2. ΔCts with GAPDH were calculated and brought to power −2. The values were normalized to the highest value where indicated.

Western previously {#s4j}
------------------

As described previously ([@b36]) with minor modifications. 1×10^6^ cell pellets were extracted in 200 µl of combined lysis/loading buffer (300 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 4.1% SDS, 20% glycerol, 0.0004% bromoblue, 175 mM Tris-Cl, 10% betamercaptoethanol), denatured 10 minutes at 98°C and incubated on ice for 5 minutes. 15 µl of extract were loaded onto a 12% Tris-HCl acrylamide gel (BioRad 161-1120), electrophoresed, and transferred to nitrocellulose membranes. Membranes were blocked in TBS containing 3% BSA. Primary antibodies were incubated overnight at 4°C. Primary antibodies used were: rabbit anti-macroH2A.1 (1 µg/ml, Abcam ab37264), rabbit anti-Histone H3 (1:4000, Abcam ab1791). After extensive TBS 0.05% Tween20 (TBS-T) washes, secondary antibody 680CW-conjugated goat anti-rabbit (LI-COR, 1:25,000) was incubated 30 minutes at room temperature. After extensive TBS-T washes, fluorescence was detected using the Odyssey® Infrared imaging system (LI-COR).

Teratoma assay {#s4k}
--------------

iPSCs were injected under the kidney capsule of anesthetized MF1 mice. Four weeks after the injection tumors were surgically dissected from the mice. Samples were fixed in PBS containing 4% formaldehyde and embedded in paraffin. Sections were stained with hematoxylin and eosin.

Blastocyst injection {#s4l}
--------------------

Standard microinjection methodology using host blastocysts of C57BL/6 strain was employed.

Statistical analysis {#s4m}
--------------------

Statistical differences were assessed with the unpaired Student\'s *t*-test. Data are presented as mean ± s.e.m. or mean ± s.d.; *P*-values less than 0.05 were considered statistically significant.
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